Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines which were referred to the Minister of Health under the provisions of section 24(5) of the Act and are set out in the Schedule hereto:
Schedule
Product: | Marevan |
Active Ingredient: | Warfarin sodium 1mg |
Dosage Form: | Tablet |
New Zealand Sponsor: | GlaxoSmithKline NZ Limited |
Manufacturer: | Douglas Manufacturing Limited, Auckland, New Zealand |
Product: | Marevan |
Active Ingredient: | Warfarin sodium 3mg |
Dosage Form: | Tablet |
New Zealand Sponsor: | GlaxoSmithKline NZ Limited |
Manufacturer: | Douglas Manufacturing Limited, Auckland, New Zealand |
Product: | Marevan |
Active Ingredient: | Warfarin sodium 5mg |
Dosage Form: | Tablet |
New Zealand Sponsor: | GlaxoSmithKline NZ Limited |
Manufacturer: | Douglas Manufacturing Limited, Auckland, New Zealand |
Product: | Zavicefta |
Active Ingredients: | Avibactam sodium 543.5mg equivalent to avibactam 500mg Ceftazidime pentahydrate 2329.7mg equivalent to ceftazidime 2000mg |
Dosage Form: | Powder for infusion concentrate |
New Zealand Sponsor: | Pfizer New Zealand Limited |
Manufacturer: | ACS Dobfar SpA, Verona, Italy |
Dated this 14th day of October 2022.
CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).